Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Pharmaceutical TechnologyDemand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Demand for HPAPIs and ADCs is accelerating, prompting CDMOs to invest to strengthen manufacturing capabilities for oncology. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remediesNext: Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Related Stories Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026 Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026
